https://www.PR.com/ Latest news releases from PR.com for Mirror Biologics, Inc. Sun, 06 Sep 2026 20:20:14 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/937348 Mon, 28 Apr 2025 07:15:54 -0400 A new approach for pandemic preparedness and protection of the elderly from any type of respiratory viral infection. Five injections over two weeks provides possible universal viral protection without need for booster shots. [PR.com] https://www.pr.com/press-release/937348 Mirror Biologics, Inc. https://www.pr.com/press-release/909972 Thu, 18 Apr 2024 09:00:00 -0400 Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over the last 13 years. She has also led teams that successfully launched public offerings over this time. In addition, she has 10 [PR.com] https://www.pr.com/press-release/909972 Mirror Biologics, Inc. https://www.pr.com/press-release/871073 Tue, 11 Oct 2022 03:00:00 -0400 Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in December 2021. Keith Loo (Loo See Yuen), the CEO of the Bradbury Group, has also now joined as a member of the Board of [PR.com] https://www.pr.com/press-release/871073 Mirror Biologics, Inc. https://www.pr.com/press-release/850741 Thu, 09 Dec 2021 03:00:00 -0500 This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. [PR.com] https://www.pr.com/press-release/850741 Mirror Biologics, Inc. https://www.pr.com/press-release/849274 Wed, 17 Nov 2021 13:48:29 -0500 Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious diseases. Unlike classic vaccines that are designed to protect against disease occurrence, therapeutic vaccines are designed to [PR.com] https://www.pr.com/press-release/849274 Mirror Biologics, Inc. https://www.pr.com/press-release/844350 Fri, 10 Sep 2021 03:00:00 -0400 Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where the active ingredients are living immune cells, announced today the clearance of the “ALIVE” Phase II/III [PR.com] https://www.pr.com/press-release/844350 Mirror Biologics, Inc. https://www.pr.com/press-release/840348 Wed, 14 Jul 2021 21:18:00 -0400 Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active ingredients are living immune cells, announced today the initiation of the ALLOPRIME universal viral vaccine Phase I/II clinical [PR.com] https://www.pr.com/press-release/840348 Mirror Biologics, Inc. https://www.pr.com/press-release/840123 Fri, 09 Jul 2021 03:00:00 -0400 Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living immune cells, today announced initiation of the STIMVAX Phase IIB, pre-registration, open-label, multi-site, clinical trial for [PR.com] https://www.pr.com/press-release/840123 Mirror Biologics, Inc.